Designing Organoid Models to Monitor Cancer Progression, Plasticity and Resistance: The Right Set Up for the Right Question
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Cell Culture
2.2. PDX Processing
2.3. Microsupport Culture
2.4. Drug Treatment
2.5. MTT Assay
2.6. Cytotoxicity Assay
2.7. Organoid Model
2.8. Histology Block Preparation
2.9. Immunofluorescence Staining
2.10. Microscopy
3. Results
3.1. A Composite Model to Optimize Functional Monitoring
3.2. Drug Treatment
3.3. Immune Cells and Immunotoxicity
4. Discussion and Conclusions
4.1. Proliferation and Migration
4.2. The Matrix Dilemna
4.3. Monitoring Drug Treatment
4.4. A New Paradigm: The Introduction of Immune Cells
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Halfter, K.; Mayer, B. Bringing 3D tumor models to the clinic—predictive value for personalized medicine. Biotechnol. J. 2017, 12, 1600295. [Google Scholar] [CrossRef]
- Perrin, S. Preclinical research: Make mouse studies work. Nature 2014, 507, 423–425. [Google Scholar] [CrossRef] [PubMed]
- Loessner, D.; Stok, K.S.; Lutolf, M.P.; Hutmacher, D.W.; Clements, J.A.; Rizzi, S.C. Bioengineered 3D platform to explore cell–ECM interactions and drug resistance of epithelial ovarian cancer cells. Biomaterials 2010, 31, 8494–8506. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matsubara, M.; Bissell, M.J. Inhibitors of Rho kinase (ROCK) signaling revert the malignant phenotype of breast cancer cells in 3D context. Oncotarget 2016, 7, 31602–31622. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asadian, S.; Piryaei, A.; Gheibi, N.; Aziz Kalantari, B.; Reza Davarpanah, M.; Azad, M.; Kapustina, V.; Alikhani, M.; Moghbeli Nejad, S.; Keshavarz Alikhani, H.; et al. Rhenium Perrhenate ((188)ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells. Cells 2022, 11, 305. [Google Scholar] [CrossRef]
- Nii, T.; Makino, K.; Tabata, Y. A Cancer Invasion Model Combined with Cancer-Associated Fibroblasts Aggregates Incorporating Gelatin Hydrogel Microspheres Containing a p53 Inhibitor. Tissue Eng. Part C Methods 2019, 25, 711–720. [Google Scholar] [CrossRef] [PubMed]
- Nii, T.; Kuwahara, T.; Makino, K.; Tabata, Y. A Co-Culture System of Three-Dimensional Tumor-Associated Macrophages and Three-Dimensional Cancer-Associated Fibroblasts Combined with Biomolecule Release for Cancer Cell Migration. Tissue Eng. Part A 2020, 26, 1272–1282. [Google Scholar] [CrossRef] [PubMed]
- Xia, X.; Li, F.; He, J.; Aji, R.; Gao, D. Organoid technology in cancer precision medicine. Cancer Lett. 2019, 457, 20–27. [Google Scholar] [CrossRef] [PubMed]
- Porter, R.J.; Murray, G.I.; McLean, M.H. Current concepts in tumour-derived organoids. Br. J. Cancer 2020, 123, 1209–1218. [Google Scholar] [CrossRef]
- Devarasetty, M.; Mazzocchi, A.R.; Skardal, A. Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future. BioDrugs 2018, 32, 53–68. [Google Scholar] [CrossRef]
- Homicsko, K. Organoid technology and applications in cancer immunotherapy and precision medicine. Curr. Opin. Biotechnol. 2020, 65, 242–247. [Google Scholar] [CrossRef] [PubMed]
- Benlalam, H.; Jalil, A.; Hasmim, M.; Pang, B.; Tamouza, R.; Mitterrand, M.; Godet, Y.; Lamerant, N.; Robert, C.; Avril, M.-F.; et al. Gap Junction Communication between Autologous Endothelial and Tumor Cells Induce Cross-Recognition and Elimination by Specific CTL. J. Immunol. 2009, 182, 2654–2664. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nii, T.; Makino, K.; Tabata, Y. Three-Dimensional Culture System of Cancer Cells Combined with Biomaterials for Drug Screening. Cancers 2020, 12, 2754. [Google Scholar] [CrossRef]
- DeVolder, R.; Kong, H.J. Hydrogels for in vivo-like three-dimensional cellular studies. Wiley Interdiscip. Rev. Syst. Biol. Med. 2012, 4, 351–365. [Google Scholar] [CrossRef]
- Gill, B.J.; West, J.L. Modeling the tumor extracellular matrix: Tissue engineering tools repurposed towards new frontiers in cancer biology. J. Biomech. 2014, 47, 1969–1978. [Google Scholar] [CrossRef]
- Kraehenbuehl, T.P.; Zammaretti, P.; Van der Vlies, A.J.; Schoenmakers, R.G.; Lutolf, M.P.; Jaconi, M.E.; Hubbell, J.A. Three-dimensional extracellular matrix-directed cardioprogenitor differentiation: Systematic modulation of a synthetic cell-responsive PEG-hydrogel. Biomaterials 2008, 29, 2757–2766. [Google Scholar] [CrossRef]
- Lee, S.H.; Shim, K.Y.; Kim, B.; Sung, J.H. Hydrogel-based three-dimensional cell culture for organ-on-a-chip applications. Biotechnol. Prog. 2017, 33, 580–589. [Google Scholar] [CrossRef] [PubMed]
- Friedman, A.A.; Letai, A.; Fisher, D.E.; Flaherty, K.T. Precision medicine for cancer with next-generation functional diagnostics. Nat. Cancer 2015, 15, 747–756. [Google Scholar] [CrossRef]
- Savagner, P. Epithelial-mesenchymal transitions: From cell plasticity to concept elasticity. Curr. Top. Dev. Biol. 2015, 112, 273–300. [Google Scholar]
- Medina, D.; Oborn, C.J.; Kittrell, F.S.; Ullrich, R.L. Properties of Mouse Mammary Epithelial Cell Lines Characterized by In Vivo Transplantation and In Vitro Immunocytochemical Methods2. JNCI J. Natl. Cancer Inst. 1986, 76, 1143–1156. [Google Scholar] [CrossRef]
- Corgnac, S.; Malenica, I.; Mezquita, L.; Auclin, E.; Voilin, E.; Kacher, J.; Halse, H.; Grynszpan, L.; Signolle, N.; Dayris, T.; et al. CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17. Cell Rep. Med. 2020, 1, 100127. [Google Scholar] [CrossRef] [PubMed]
- Idoux-Gillet, Y.; Nassour, M.; Lakis, E.; Bonini, F.; Theillet, C.; du Manoir, S.; Savagner, P. Slug/Pcad pathway controls epithelial cell dynamics in mammary gland and breast carcinoma. Oncogene 2018, 37, 578–588. [Google Scholar] [CrossRef]
- Deugnier, M.A.; Faraldo, M.M.; Teulière, J.; Thiery, J.P.; Medina, D.; Glukhova, M.A. Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-Dbeta cell line. Dev. Biol. 2006, 293, 414–425. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shamir, E.; Ewald, A.J. Three-dimensional organotypic culture: Experimental models of mammalian biology and disease. Nat. Rev. Mol. Cell Biol. 2014, 15, 647–664. [Google Scholar] [CrossRef]
- Nassour, M.; Idoux-Gillet, Y.; Selmi, A.; Côme, C.; Faraldo, M.-L.M.; Deugnier, M.-A.; Savagner, P. Slug Controls Stem/Progenitor Cell Growth Dynamics during Mammary Gland Morphogenesis. PLoS ONE 2012, 7, e53498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dahlberg, C.I.M.; Sarhan, D.; Chrobok, M.; Duru, A.D.; Alici, E. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. Front. Immunol. 2015, 6, 605. [Google Scholar] [CrossRef] [Green Version]
- Dzamba, B.J.; DeSimone, D.W. Extracellular Matrix (ECM) and the Sculpting of Embryonic Tissues. Curr. Top. Dev. Biol. 2018, 130, 245–274. [Google Scholar]
- Vaillant, F.; Lindeman, G.J.; Visvader, J.E. Jekyll or Hyde: Does Matrigel provide a more or less physiological environment in mammary repopulating assays? Breast Cancer Res. 2011, 13, 108–111. [Google Scholar] [CrossRef]
- Aisenbrey, E.A.; Murphy, W.L. Synthetic alternatives to Matrigel. Nat. Rev. Mater. 2020, 5, 539–551. [Google Scholar] [CrossRef]
- Hernandez-Gordillo, V.; Kassis, T.; Lampejo, A.; Choi, G.; Gamboa, M.E.; Gnecco, J.S.; Brown, A.; Breault, D.T.; Carrier, R.; Griffith, L.G. Fully synthetic matrices for in vitro culture of primary human intestinal enteroids and endometrial organoids. Biomaterials 2020, 254, 120125. [Google Scholar] [CrossRef]
- Lee, H.J.; Mun, S.; Pham, D.M.; Kim, P. Extracellular Matrix-Based Hydrogels to Tailoring Tumor Organoids. ACS Biomater. Sci. Eng. 2021, 7, 4128–4135. [Google Scholar] [CrossRef] [PubMed]
- Weeber, F.; Ooft, S.N.; Dijkstra, K.K.; Voest, E.E. Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery. Cell Chem. Biol. 2017, 24, 1092–1100. [Google Scholar] [CrossRef] [PubMed]
- Yan, H.H.N.; Siu, H.C.; Law, S.; Ho, S.L.; Yue, S.S.K.; Tsui, W.Y.; Chan, D.; Chan, A.S.; Ma, S.; Lam, K.O.; et al. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening. Cell Stem Cell 2018, 23, 882–897.e811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaur, S.; Kaur, I.; Rawal, P.; Tripathi, D.M.; Vasudevan, A. Non-matrigel scaffolds for organoid cultures. Cancer Lett. 2021, 504, 58–66. [Google Scholar] [CrossRef] [PubMed]
- Ooft, S.N.; Weeber, F.; Dijkstra, K.K.; McLean, C.M.; Kaing, S.; Van Werkhoven, E.; Schipper, L.; Hoes, L.; Vis, D.J.; Van De Haar, J.; et al. Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Transl. Med. 2019, 11, eaay2574. [Google Scholar] [CrossRef] [PubMed]
- Krause, S.; Jondeau-Cabaton, A.; Dhimolea, E.; Soto, A.M.; Sonnenschein, C.; Maffini, M.V. Dual Regulation of Breast Tubulogenesis Using Extracellular Matrix Composition and Stromal Cells. Tissue Eng. Part A 2012, 18, 520–532. [Google Scholar] [CrossRef] [Green Version]
- Costa, A.; Kieffer, Y.; Scholer-Dahirel, A.; Pelon, F.; Bourachot, B.; Cardon, M.; Sirven, P.; Magagna, I.; Fuhrmann, L.; Bernard, C.; et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 2018, 33, 463–479.e10. [Google Scholar] [CrossRef] [Green Version]
- Nguyen, M.; De Ninno, A.; Mencattini, A.; Mermet-Meillon, F.; Fornabaio, G.; Evans, S.S.; Cossutta, M.; Khira, Y.; Han, W.; Sirven, P.; et al. Dissecting Effects of Anti-cancer Drugs and Cancer-Associated Fibroblasts by On-Chip Reconstitution of Immunocompetent Tumor Microenvironments. Cell Rep. 2018, 25, 3884–3893.e3. [Google Scholar] [CrossRef] [Green Version]
- Sachs, N.; de Ligt, J.; Kopper, O.; Gogola, E.; Bounova, G.; Weeber, F.; Balgobind, A.V.; Wind, K.; Gracanin, A.; Begthel, H.; et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell 2018, 172, 373–386.e10. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Doffe, F.; Bonini, F.; Lakis, E.; Terry, S.; Chouaib, S.; Savagner, P. Designing Organoid Models to Monitor Cancer Progression, Plasticity and Resistance: The Right Set Up for the Right Question. Cancers 2022, 14, 3559. https://doi.org/10.3390/cancers14153559
Doffe F, Bonini F, Lakis E, Terry S, Chouaib S, Savagner P. Designing Organoid Models to Monitor Cancer Progression, Plasticity and Resistance: The Right Set Up for the Right Question. Cancers. 2022; 14(15):3559. https://doi.org/10.3390/cancers14153559
Chicago/Turabian StyleDoffe, Flora, Fabien Bonini, Emile Lakis, Stéphane Terry, Salem Chouaib, and Pierre Savagner. 2022. "Designing Organoid Models to Monitor Cancer Progression, Plasticity and Resistance: The Right Set Up for the Right Question" Cancers 14, no. 15: 3559. https://doi.org/10.3390/cancers14153559